CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 920,359	$ 809,102
Marketable securities	488,032	236,121
Accounts receivable - trade, net	1,332,071	1,152,489
Accounts Receivable from Sanofi	124,107	153,152
Accounts receivable from Bayer	187,694	162,152
Inventories	345,620	238,578
Prepaid expenses and other current assets	103,806	163,501
Total current assets	3,501,689	2,915,095
Marketable securities	777,906	632,162
Property, plant, and equipment, net	1,872,167	1,594,120
Deferred tax assets	655,552	461,945
Other assets	20,705	5,810
Total assets	6,828,019	5,609,132
Current liabilities:
Accounts payable and accrued expenses	714,916	644,112
Deferred revenue from Sanofi, current portion	105,041	101,573
Deferred revenue - other, current portion	137,642	51,914
Other current liabilities	3,586	13,563
Total current liabilities	961,185	811,162
Deferred revenue from Sanofi	529,791	582,664
Deferred Revenue - other	327,868	82,015
Facility lease obligations	382,228	362,919
Other long-term liabilities	135,700	115,535
Total liabilities	2,336,772	1,954,295
Stockholders' equity:
Preferred Stock	0	0
Additional paid-in capital	3,314,982	3,099,526
Retained earnings	1,495,107	852,700
Accumulated other comprehensive (loss) income	(2,899)	8,572
Treasury stock	(316,052)	(306,069)
Total stockholders' equity	4,491,247	3,654,837
Total liabilities and stockholders' equity	6,828,019	5,609,132
Class A Stock
Stockholders' equity:
Common stock	2	2
Common Stock
Stockholders' equity:
Common stock	$ 107	$ 106